A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor
Interventions: BIOLOGICAL: CDK-002
Sponsor: Codiak BioSciences